<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925324</url>
  </required_header>
  <id_info>
    <org_study_id>STEMVAD-001</org_study_id>
    <nct_id>NCT03925324</nct_id>
  </id_info>
  <brief_title>Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device</brief_title>
  <acronym>STEM-VAD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and preliminary efficacy of serial intravenous dose of&#xD;
      Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left&#xD;
      ventricular assist devices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, single-center, randomized study to assess the safety and&#xD;
      preliminary efficacy of a three serial intravenous doses of allogeneic mesenchymal bone&#xD;
      marrow cells to subjects with heart failure and implanted left ventricular assist devices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temperature</measure>
    <time_frame>up to 12 months post enrollment</time_frame>
    <description>Temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncontrolled systemic infection</measure>
    <time_frame>up to 12 months post enrollment</time_frame>
    <description>Number of admission for uncontrolled systemic infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 12 months post enrollment</time_frame>
    <description>Rate of Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NK cell depletion</measure>
    <time_frame>Baseline to day 90</time_frame>
    <description>percent reduction in NK cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the following cardiac biomarker</measure>
    <time_frame>Baseline and day 90 post initial infusion</time_frame>
    <description>The change in the lab values N-Terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV systolic function</measure>
    <time_frame>Baseline and day 90 post initial infusion</time_frame>
    <description>Change in RV systolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations due to right heart failure</measure>
    <time_frame>day 90</time_frame>
    <description>Number of hospitalizations for to right heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance changes</measure>
    <time_frame>Baseline and day 90 post initial infusion</time_frame>
    <description>6 minute walk distance changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gout flares</measure>
    <time_frame>Day 90</time_frame>
    <description>Count of gout flares</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)</intervention_name>
    <description>Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg</description>
    <arm_group_label>Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1.5 mL/kg Lactated Ringer's Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Advanced Heart Failure&#xD;
&#xD;
          3. Advanced HF defined as HF requiring LVAD implantation and deemed stable on his/her&#xD;
             LVAD.&#xD;
&#xD;
          4. On stable medical therapy (per the discretion of the treating physician) including&#xD;
             beta-blockers, ACE-inhibitors, angiotensin receptors blockers, angiotensin receptor&#xD;
             neprilysin inhibitor, mineralocorticoid receptor antagonists, isosorbide, hydralazine,&#xD;
             and mineralocorticoid receptor antagonists) and optimized pump speed for at least a&#xD;
             month prior to randomization.&#xD;
&#xD;
          5. HS-CRP level≥2 mg/l.&#xD;
&#xD;
          6. NYHA class II-III symptoms.&#xD;
&#xD;
          7. Ability to understand and provide signed informed consent.&#xD;
&#xD;
          8. Reasonable expectation that patient will receive standard post-treatment care and&#xD;
             attend all scheduled safety follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women of childbearing potential. Postmenopausal women or women with permanent&#xD;
             contraception method (defined as total hysterectomy) will not be excluded.&#xD;
&#xD;
          2. History of debilitating stroke (modified Rankin Score &gt; 3) within 3 months.&#xD;
&#xD;
          3. The likelihood of requirement of cardiac surgery during the study period.&#xD;
&#xD;
          4. Presence of clinically significant, uncorrected left sided valvular heart disease,&#xD;
             active acute myocarditis, or uncontrolled hypertension defined as Persistently&#xD;
             elevated mean arterial blood pressure (&gt;100 mmHg). Echocardiography within 12 months&#xD;
             of screening. Patients can be re-evaluated, at the discretion of the investigator.&#xD;
&#xD;
          5. QTc &gt;550 ms (in the absence of bundle branch block, interventricular conduction delay&#xD;
             or ventricular pacing). Electrocardiogram (ECG) within 60 days.&#xD;
&#xD;
          6. History of cardiac arrest within 3 months.&#xD;
&#xD;
          7. Hypertrophic or infiltrative cardiomyopathy.&#xD;
&#xD;
          8. Considered or listed for organ transplantation or history of organ transplantation&#xD;
&#xD;
          9. Illness other than HF with life expectancy less than 12 months.&#xD;
&#xD;
         10. Enrolled in an interventional trial or received an experimental drug or device within&#xD;
             30 days of randomization.&#xD;
&#xD;
         11. Left ventricular assist device implantation &gt;2 years prior to enrollment.&#xD;
&#xD;
         12. Biventricular assist device (Bi-VAD) support.&#xD;
&#xD;
         13. Severe COPD defined by FEV1&lt;1L, FEV1/FVC&lt;70% within 12 months if known history of&#xD;
             COPD, otherwise FEV1&lt;1L, FEV1/FVC&lt;70% within 24 months&#xD;
&#xD;
         14. Uncontrolled seizure disorder.&#xD;
&#xD;
         15. Clinically significant hematologic, hepatic, or renal impairment as determined by&#xD;
             screening clinical laboratory tests within the last 30 days:&#xD;
&#xD;
             Liver disease = ALT or AST &gt; 3x normal, alkaline phosphatase or bilirubin &gt;2x normal&#xD;
             Renal disease = on long term dialysis Hematologic = Unexplained persistent&#xD;
             leukocytosis (WBC &gt;11 K/UL) or hemoglobin &lt; 8.5 gm/dl&#xD;
&#xD;
         16. Presence of any other clinically-significant medical condition, psychiatric condition,&#xD;
             or laboratory abnormality, that in the judgment of the investigator or sponsor may&#xD;
             affect compliance with the study protocol or pose a safety risk to the subject.&#xD;
&#xD;
         17. Inability to comply with the conditions of the protocol.&#xD;
&#xD;
         18. Acute coronary syndrome within 4 weeks (clinical diagnosis, confirmed by&#xD;
             electrocardiographic abnormalities and elevation of troponin-I).&#xD;
&#xD;
         19. Malignancy within the previous five years, except adequately treated basal cell&#xD;
             carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in&#xD;
             situ of the cervix.&#xD;
&#xD;
         20. Active uncontrolled systemic infection. Positive blood or deep tissue cultures or&#xD;
             clinical or imaging evidence of systemic infection despite complete course of&#xD;
             effective antimicrobial therapy as determined by infectious diseases. Localized&#xD;
             (non-systemic) infection is not an exclusion criterion. Patients can be re-evaluated,&#xD;
             at the discretion of the investigator.&#xD;
&#xD;
         21. Early postpartum cardiomyopathy (within six months of diagnosis).&#xD;
&#xD;
         22. Presence of inherited or acquired immune deficiency or human immunodeficiency virus&#xD;
             infection (HIV). Negative HIV test within the preceding 12 months is required.&#xD;
&#xD;
         23. Systemic corticosteroids, immunosuppressive drug therapy (cyclophosphamide,&#xD;
             methotrexate, cyclosporine, tacrolimus, azathioprine, mycophenolate, sirolimus, etc.),&#xD;
             and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.&#xD;
&#xD;
         24. Known Porphyria.&#xD;
&#xD;
         25. Allergy to sodium citrate or any caine type of local anesthetic.&#xD;
&#xD;
         26. Patient enrolled in hospice care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

